MediWound (NASDAQ:MDWD) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of MediWound (NASDAQ:MDWD - Free Report) in a research report report published on Monday. The brokerage issued an outperform rating and a $34.00 price target on the biopharmaceutical company's stock.

A number of other equities analysts also recently commented on MDWD. Wall Street Zen raised MediWound to a "sell" rating in a research report on Friday, March 21st. Alliance Global Partners assumed coverage on MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 price objective for the company. HC Wainwright set a $31.00 price objective on MediWound and gave the stock a "buy" rating in a research report on Thursday, May 22nd. Finally, Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They set a "buy" rating and a $39.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $31.80.

MediWound Stock Down 0.2%

NASDAQ MDWD traded down $0.04 during trading on Monday, hitting $21.66. The stock had a trading volume of 25,132 shares, compared to its average volume of 91,547. The company has a market capitalization of $234.10 million, a PE ratio of -7.47 and a beta of 0.30. The firm has a 50 day moving average price of $18.21 and a 200 day moving average price of $17.87. MediWound has a twelve month low of $12.78 and a twelve month high of $24.00.

MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.58. The company had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the previous year, the company posted ($1.05) EPS. On average, sell-side analysts anticipate that MediWound will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On MediWound

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its holdings in MediWound by 94.6% in the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock valued at $2,577,000 after purchasing an additional 70,367 shares in the last quarter. Rhumbline Advisers boosted its holdings in MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after purchasing an additional 739 shares in the last quarter. Barclays PLC boosted its holdings in MediWound by 11.2% in the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company's stock valued at $221,000 after purchasing an additional 1,249 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in MediWound by 154.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 1,162 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in MediWound by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company's stock valued at $1,757,000 after purchasing an additional 3,408 shares in the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.